Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 FY20 Earnings Presentation
19 slides from Eris Lifesciences's earnings presentation, Feb 14, 2020
Slide 1: Exchange filing cover letter: Investor Presentation
Date: February 14, 2020 To To The Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai- 400001 Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION
Slide 2: Eris Lifesciences Ltd Q3 FY20 Investor Presentation
ERIS LIFESCIENCES LTD Q3 FY 20 INVESTOR PRESENTATION 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: Moment of Pride: India Heart Study in International Journal
MOMENT OF PRIDE ERIS’ INDIA HEART STUDY IN INTERNATIONAL JOURNAL Our persistent efforts to promote science recognised by global institutions of hypertension European Society of Hypertension and International Society of Hypertension have jointly accepted our India Heart Study paper to publish in the
Slide 5: Patient Care Initiatives – Scientific Engagement with Doctors
PATIENT CARE INITIATIVES – SCIENTIFIC ENGAGEMENT WITH DOCTORS Scientific engagement with Doctors – our marketing divisions maintain their tenacious focus on Patient Care Initiatives while engaging with health care providers. This investment in promotion of science provides Eris an unhindered mindspa
Slide 6: The quarter sees Substantial Investment in Growth
Q3 FY 20 – BUSINESS HIGHLIGHTS The quarter sees Substantial Investment in Growth Capitalising Patent New Products Expansion of Off patent Protected Eris forays into launched for Field Force opportunities In licensed Generics brand life cycle 219 BEs added successfully products management successfull
Slide 7: Successfully Capitalising Off patent opportunities
Q3 FY 20 – BUSINESS HIGHLIGHTS Substantial Investment in Growth Successfully Capitalising Off patent opportunities In December 2019, Vildagliptin, a prime molecule in Diabetes Care, went off patent. Vildagliptin is a DPP 4 inhibitor – a class of oral diabetes drug that has evolved as the first line
Slide 8: Substantial Investment in Growth
Q3 FY 20 – BUSINESS HIGHLIGHTS Substantial Investment in Growth In Q3 FY 20 we launched Rariset, under our in-licensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron Successful launch of Iron has a crucial role in Ante Natal Care as well as management of chronic diseas
Slide 9: Substantial Investment in Growth: 219 BEs added in Q3 FY20
Q3 FY 20 – BUSINESS HIGHLIGHTS Substantial Investment in Growth 219 BEs 2,364 added in Q3 FY 20 219 BEs added in Q3 FY 20 145 BEs added in H1 FY 20 2,145 2 new divisions launched Aspire for Zomelis with 186 BEs 2,000 and another for foray into Generics with 25 BEs HR Expenses FY 19 H1 20 Q3 20 Inves
Slide 10: Guwahati plant to cater to ≈80% of total revenue from Q1 FY21
Q3 FY 20 – BUSINESS HIGHLIGHTS Guwahati plant to cater to ≈ 80% of total revenue from Q1 FY 21 onwards Soft Gelatin products to move to Guwahati by % Contribution of Guwahati Plant to Total Revenue Q4 FY 20/ Q1 FY 21 80% 70% 65% Nutraceuticals and other products made in 60% Guwahati Facility enjoys
Slide 11: Business Redefined into 5 SBUs
Q3 FY 20 – BUSINESS HIGHLIGHTS Business Redefined into 5 SBUs With Distinct SBU Heads CARDIO CARDIO NEWER METABOLIC METABOLIC CNS ACUTE BUSINESSES BUSINESSES -1 BUSINESSES -2 10
Slide 12: Q3 FY20 – Secondary Growth
Q3 FY 20 – SECONDARY GROWTH IPM ERIS 9.5% IPM grew by Eris’s total sales TOTAL 6.4% 9.5%... grew by 6.4% 10.0% IPM’s Acute therapies, which To bring sharper focus on have historically grown less Acute Therapies, Eris creates 14% of Eris’ than chronic therapies for an SBU for acute business with ACUT
Slide 13: 9m FY20 – Secondary Growth
9m FY 20 – SECONDARY GROWTH IPM ERIS 10.2% IPM grew by Eris’s total sales 9.8% TOTAL 9.8%... grew by 10.2% To bring sharper focus on 9.9% Acute Therapies, Eris creates -1.1% 14% of Eris’ IPM’s Acute therapies grew at an SBU for acute business with ACUTE Revenue 9.9% a new SBU Head now managing this
Slide 14: Q3 FY20 – Prescription Ranking
Q3 FY 20 - PRESCRIPTION RANKING Prescription Ranking* 5 3 3 CARDIOLOGY DIABETOLOGY GASTRO 3 8 CONSULTING NEUROLOGY PHYSICIAN Source: SMSRC Nov-Dec’19 * Rx Rank in Represented Market (Rx Nov-Dec’19) 13
Slide 15: Q3 FY20 and 9m FY20 – Financial Highlights
Q3 FY 20 and 9m FY 20 – FINANCIAL HIGHLIGHTS Q3 FY 20 Financial Performance 5.3 % -17.9 % -20.9 % yoy growth in Sales yoy growth in EBITDA yoy growth in Net Profit • Incremental investments in growth lead to dilution of Ebitda margin from 37.1% to 28.8% • Eris Acquires Zomelis trademark from Novarti
Slide 16: Q3 FY20 and 9m FY20 – Income Statement
Q3 FY 20 and 9m FY 20 – INCOME STATEMENT Consolidated Q3 FY 20 9m FY 20 Q3 FY 20 Q3 FY 19 9m FY 20 9m FY 19 INR millions yoy GR yoy GR Sale of Products 2,618 2,485 5.3% 8,141 7,561 7.7% Other Operating Income 46 39 18.6% 114 112 1.5% Revenue from Operations 2,664 2,524 5.5% 8,255 7,673 7.6% Gross Pr
Slide 17: 10 Year Financial Highlight
10 YEAR FINANCIAL HIGHLIGHT 12,000 4.16 4.50 4.10 3.77 4.00 3.62 9,822 10,000 3.50 8,556 3.50 2.95 3.03 8,255 8,000 2.75 7,495 3.00 2.42 2.18 5,970 2.50 6,000 5,456 5,088 2.00 1.58 3,931 4,000 1.50 2,739 0.76 2,054 1.00 2,000 955 0.50 356 - - FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 9m
Slide 18: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Sr no Name of Shareholder 31-Dec-19 30-Sep-2019 30-Jun-2019 Others, 0.50% FPIs, 8.85% 474* 451* 509* Promoters 56.23% 56.23% 56.23% 1 Aditya Birla Sun Life Mutual Fund 3.78% 3.85% 3.84% DIIs, 11.80% 2
Slide 19: Thank You
THANK YOU ERIS LIFESCIENCES LTD KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 18